In May, QIAGEN cofounder Dr. Detlev Riesner stepped down from the Supervisory Board. Dr. Elaine Mardis, codirector of the Genome Institute at Washington University and the Robert E. and Louise F. Dunn Distinguished Professor of Medicine, was proposed as a new member.
Endress+Hauser revenues rose over 7% in 2013 to €1.8 billion ($2.4 billion). Operating profit totaled €277 million ($369 million). Net income was a record €187 million ($249 million). The company is targeting revenues of €2.1 billion ($2.8 billion) for 2014, including 9% organic growth.
In May, Endress+Hauser named three new members to its administrative body: Hans-Peter Endress, son of the company founder; Thomas Kraus, formerly with TNT Express; and Antonietta Pedrazzetti, who works at Roche Diagnostics.
Agilent Technologies announced a collaboration with Seoul National University on a new research center to support the College of Pharmacy’s New Drug Development Center. Agilent will provide bioanalytical instruments and expertise in pharmaceutical-drug testing and multi-omic biological systems. The center will serve as Agilent’s reference site for drug development.
Transgenomic named John D. Thompson to its Board in May. He was previously senior vice president, Strategy and Corporate Development, at Invitrogen.
Thermo Fisher Scientific announced a collaboration with the USDA’s Agricultural Research Service and Pennsylvania State University to develop rapid methods to detect E. coli in food with the aim of detecting the bacterium in meat products using next-generation sequencing and PCR products. Thermo Fisher’s Life Technologies Ion Personal Genome Machine will be used to sequence DNA from approximately 200 strains.
The Hindu Business Line reported in June that Thermo Fisher Scientific opened a 1,800 ft2 customer center in Bangalore, India, for life science. It has a staff of 40.
PerkinElmer agreed in May to become the exclusive global distributor of Sebia’s CAPILLARYS 2 NEONAT FAS hemoglobin-screening offering to newborn-screening labs.
PerkinElmer announced in June that it will serve as the exclusive collaborator with China’s National Health and Family Planning Commission in developing and implementing a three-year newborn-screening program focused on early detection of life-threatening disorders. PerkinElmer screened more than nine million babies in China last year.
Shimadzu (Asia Pacific) and the National University of Singapore Environmental Research Institute (NERI) signed a memorandum of understanding to establish a joint facility to conduct environmental analytical research. Shimadzu will contribute instrumentation and, with NERI, will develop and fully automate sample-preparation procedures integrated with MS for water-quality monitoring.